PHARMACY

Report: CVS Health subsidiary RxCrossroads expanding specialty services reach

BY DSN STAFF
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

AbbVie grows oncology pipeline with Stemcentrx acquisition

BY David Salazar
NORTH CHICAGO — Biopharmaceutical company AbbVie on Thursday announced its planned acquisition of Stemcentrx and its late-stage potential treatment for small cell lung cancer, Rova-T (rovalpituzumab tesirine). 
 
“AbbVie is committed to continued innovation in oncology, a critical component of our long-term growth and an area of significant need to millions of patients worldwide,” AbbVie chairman and CEO Richard Gonzalez said. “The addition of Stemcentrx and its late-stage compound Rova-T provide AbbVie with a unique platform in solid tumor therapeutics and complement our leadership position in hematologic oncology. We believe the acquisition of Stemcentrx will strengthen and accelerate our ability to deliver innovative therapies that will have a remarkable impact on patients' lives.”
 
Rova-T is under investigation as a potential third-line treatment for SCLC, for which there isn’t an approved therapy and it has been submitted to the Food and Drug Administration for consideration for Breakthrough Therapy designation. 
 
“We are thrilled to be joining the AbbVie team and believe that, together, we can bring much-needed therapies to cancer patients," Stemcentrx founder and CEO Brian Slingerland said. “AbbVie, with its long-term commitment and expertise in drug development, will help us turn our scientific discoveries into a mainstay of cancer treatments."
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

iMedicare reports saving patients $287.5 million in 2015

BY David Salazar

NEW YORK — Medicare plan comparison platform iMedicare on Thursday announced that in 2-15 it helped more than 250,000 patients save an average of $1,150 on their expected Medicare Part D costs — a collective savings of $287.5 million. 

iMedicare’s platform allows pharmacies to easily compare Medicare plan options for patients based on their medication needs, costs and plan service area. 
 
“Around 80% of Medicare patients can save money each year by finding a more affordable Medicare plan. We are excited that our pharmacies went above and beyond to identify these patients and deliver such immense savings,” says Nathan Shanor, CFO of iMedicare. “As the Medicare population continues to grow, we look forward to iMedicare pharmacies yielding even greater results.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?